EMA/15344/2024

European Medicines Agency decision

P/0015/2024

of 31 January 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral for dordaviprone (EMEA-003389-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0015/2024

of 31 January 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral for dordaviprone (EMEA-003389-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Chimerix IRL Limited on 18 January 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 December 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for dordaviprone, capsule, hard, age-appropriate oral solid dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for dordaviprone, capsule, hard, age-appropriate oral solid dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Chimerix IRL Limited, 10 Earlsfort Terrace Dublin 2 Co. Dublin, D02 T380 – Dublin, Ireland.

EMA/PDCO/417372/2023
Amsterdam, 15 December 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-003389-PIP01-23

Scope of the application

Active substance(s):

Dordaviprone

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of glioma

Pharmaceutical form(s):

Capsule, hard

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Chimerix IRL Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Chimerix IRL Limited submitted for agreement to the European Medicines Agency on 18 January 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 27 February 2023.

Supplementary information was provided by the applicant on 7 September 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of glioma

2.1.1. Indication(s) targeted by the PIP

Treatment of H3 K27M-mutant glioma.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age-appropriate solid formulation for constitution with liquid or sprinkling on soft food be used in children from birth to less than 18 years of age.
Non-clinical studies	Not applicable
Clinical studies	**Study 2 (ONC014)** Multicentre, open-label, dose escalation and dose expansion study to assess the safety, pharmacokinetics and antitumour activity of dordaviprone as single agent in paediatric patients from 2 years to less than 18 years of age (and in adults) with relapsed or refractory H3 K27M-mutant glioma or in monotherapy and in combination with radiotherapy in paediatric patients from 2 years to less than 18 years of age (and in adults) with newly-diagnosed diffuse infiltrative pontine glioma **Study 3 (ONC201-108)** Multicentre, double-blind, placebo-controlled study to assess the safety and efficacy of dordaviprone administered once-weekly or twice-weekly in paediatric patients from birth to less than 18 years of age (and in adults) with newly-diagnosed H3 K27M-mutant diffuse glioma who have completed standard front-line therapy

Modelling and simulation studies	**Study 4** Population PK modelling and simulation study to determine the PK characteristics of dordaviprone and to identify the target efficacious exposures in paediatric patients from 2 years to less than 18 years of age with newly-diagnosed H3 K27M-mutant diffuse glioma to be assessed in study ONC201-108 (PIP study 3). **Study 5** Physiological based population pharmacokinetic model to identify the dose/dose-regimen of dordaviprone to be used in paediatric patients from birth to less than 2 years of age with newly-diagnosed H3 K27M-mutant diffuse glioma
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community